Genmab — Januar 2021
-
Kursen er vel tæt på at ligge over snit af analytikernes targets. Så enten skal analytikerne til at hæve yderligere, eller også skal de til at sige hold.
-
Giv dem tid, de skal jo lige regne på det. Snittet på de nyeste 5, som alle er fra 2021, men før godkendelsen er indtil videre på 2.839 - eller skal vi bare sige over de 2.800
($kurs) og så er der lige MS som bekræfter et mål der er lidt under kursen idag. -
der er vel noget i retningen af 15 analyser der ikke er ældre end 2 mdrs tid.
-
small new trial: FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia https://clinicaltrials.gov/ct2/show/NCT04714372 https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft538/
-
Genmab's neighbour Merus NV Announce Collaboration with Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. https://ir.merus.nl/news-releases/news-release-details/lilly-and-merus-nv-announce-collaboration-discover-novel-t-cell
-
-
https://www.jnj.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations
Nej, der er vist ikke RTOR på Amivantamab. Det var en fejl fra min side. Her JNJs pm -
Nej, på ph1 studie ved navn CHRYSALIS
-
hvad forventer vi den 26/1 mht Kesimpta?? Er der nogen ide om, hvor højt salget er
?? -
for q4
-
Er Novartis begyndt kræve betaling?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind